NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China

Reuters

Sep 04

NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China

NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564328513"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564328513\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564328513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564328513","market":"nz","top_or_hot":-1,"title":"NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and <a href=\"https://laohu8.com/S/OCUTF\">Ocumension Therapeutics</a>. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and <a href=\"https://laohu8.com/S/OCUTF\">Ocumension Therapeutics</a>. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL1L12kY:1","article_id":"2564328513","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564328513","pubTimestamp":1756963830,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application  submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK1191":"制药","01477":"欧康维视生物-B","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK1574":"生物医药B类股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"NicOx SA宣布NCX 470在美国和中国成功进行3期试验并即将提交NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":0.9,"NDAQ":0.9},"content_text":"NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    \n\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}